LONDON (Reuters) - AstraZeneca said European regulators had approved Xigduo for type 2 diabetes, in what was the first green light for a fixed dose combination of a SGLT2 inhibitor and metformin. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback